Drugs / PF-08046050
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06131840 | Nov 2023 → Sep 2029 expected | colorectal neoplasm, gastric neoplasm, gastroesophageal junction adenocarcinoma, non-small cell lung carcinoma +2 | Pfizer | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-08046050 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06131840 ↗ |